Difference between revisions of "MOC31"
Jump to navigation
Jump to search
(create) |
|||
| Line 5: | Line 5: | ||
==Negative== | ==Negative== | ||
*[[Hepatocellular carcinoma]].<ref name=pmid10937059/> | *[[Hepatocellular carcinoma]].<ref name=pmid10937059/> | ||
*[[Malignant mesothelioma|Malignant epithelioid mesothelioma]] - usually negative.<ref name=pmid9490276/> | |||
==Positive== | ==Positive== | ||
*[[Cholangiocarcinoma]].<ref name=pmid10937059/> | *[[Cholangiocarcinoma]].<ref name=pmid10937059/> | ||
*[[Liver metastases]].<ref name=pmid10937059/> | *[[Liver metastases]].<ref name=pmid10937059/> | ||
*[[Lung adenocarcinoma]].<ref name=pmid9490276>{{Cite journal | last1 = Ordóñez | first1 = NG. | title = Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. | journal = Hum Pathol | volume = 29 | issue = 2 | pages = 166-9 | month = Feb | year = 1998 | doi = | PMID = 9490276 }}</ref> | |||
==See also== | ==See also== | ||
Revision as of 17:01, 4 February 2015
MOC31 is an immunostain.
It is useful for differentiating hepatocellular carcinoma from cholangiocarcinoma and liver metastases.[1]
Negative
- Hepatocellular carcinoma.[1]
- Malignant epithelioid mesothelioma - usually negative.[2]
Positive
See also
References
- ↑ 1.0 1.1 1.2 1.3 Proca, DM.; Niemann, TH.; Porcell, AI.; DeYoung, BR. (Jun 2000). "MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers.". Appl Immunohistochem Mol Morphol 8 (2): 120-5. PMID 10937059.
- ↑ 2.0 2.1 Ordóñez, NG. (Feb 1998). "Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.". Hum Pathol 29 (2): 166-9. PMID 9490276.